EGFR and FGFR in Growth and Metastasis of Colorectal Cancer

Dariya, Begum; Merchant, Neha; Aliya, Sheik; Alam, Afroz; Nagaraju, Ganji Purnachandra

doi:10.1007/978-981-13-1486-5_11

Cited by 3 publications

(2 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, early intervention for primary CRC contributes to clinical benefit outcomes (Koncina et al, 2020). At present, the main treatment methods for CRC are tumor resection, radiotherapy, chemotherapy, anti-angiogenic therapy, targeted therapy and immunotherapy (Rejhova et al, 2018;Piawah and Venook, 2019;Dariya et al, 2020;Johdi and Sukor, 2020). Although a certain degree of success has been achieved with these treatments, several significant challenges remain to be addressed.…”

Section: Introductionmentioning

confidence: 99%

Identification of a novel lipid metabolism-related gene signature for predicting colorectal cancer survival

et al. 2022

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a common malignant tumor worldwide. Lipid metabolism is a prerequisite for the growth, proliferation and invasion of cancer cells. However, the lipid metabolism-related gene signature and its underlying molecular mechanisms remain unclear. The aim of this study was to establish a lipid metabolism signature risk model for survival prediction in CRC and to investigate the effect of gene signature on the immune microenvironment. Lipid metabolism-mediated genes (LMGs) were obtained from the Molecular Signatures Database. The consensus molecular subtypes were established using “ConsensusClusterPlus” based on LMGs and the cancer genome atlas (TCGA) data. The risk model was established using univariate and multivariate Cox regression with TCGA database and independently validated in the international cancer genome consortium (ICGC) datasets. Immune infiltration in the risk model was developed using CIBERSORT and xCell analyses. A total of 267 differentially expressed genes (DEGs) were identified between subtype 1 and subtype 2 from consensus molecular subtypes, including 153 upregulated DEGs and 114 downregulated DEGs. 21 DEGs associated with overall survival (OS) were selected using univariate Cox regression analysis. Furthermore, a prognostic risk model was constructed using the risk coefficients and gene expression of eleven-gene signature. Patients with a high-risk score had poorer OS compared with patients in the low-risk score group (p = 3.36e-07) in the TCGA cohort and the validationdatasets (p = 4.03e-05). Analysis of immune infiltration identified multiple T cells were associated with better prognosis in the low-risk group, including Th2 cells (p = 0.0208), regulatory T cells (p = 0.0425), and gammadelta T cells (p = 0.0112). A nomogram integrating the risk model and clinical characteristics was further developed to predict the prognosis of patients with CRC. In conclusion, our study revealed that the expression of lipid-metabolism genes were correlated with the immune microenvironment. The eleven-gene signature might be useful for prediction the prognosis of CRC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of a novel lipid metabolism-related gene signature for predicting colorectal cancer survival

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Therapy against FGFR2 and its specific isoforms are being considered as novel treatment options for colorectal cancer patients. By administering shRNA to bind FGFR2, CRC development, invasion, and migration can be reduced [12]. 4.…”

mentioning

confidence: 99%

EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges

et al. 2022

View full text Add to dashboard Cite

Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are diagnosed at advanced stages with metastasis—this poses challenges for effective surgical control and future tumor-related mortality. There are numerous diagnostic methods that can be used to reduce the risk of colorectal carcinoma. Among these, targeted nanotherapy aims to eliminate the tumor and any metastasis. Active targeting can increase the effectiveness and quantity of drugs delivered to the target site. Antibodies that target overexpressed receptors on cell surfaces and indicators are coupled with drug-loaded carriers. The major target receptors of chemotherapeutic drugs delivery include VEGFR, EGFR, FGFR, HER2, and TGF. On account of its major and diverse roles in cancer, it is important to target EGFR in particular for better tumor selection, as EGFR is overexpressed in 25 to 82% of colorectal carcinoma cases. The EGFR monoclonal immunoglobulins cetuximab/panitumumab can thus be used to treat colorectal cancer. This review examines carriers that contain cetuximab-conjugated therapeutic drugs as well as their efficacy in anticancer activities.

show abstract